晚期EGFR阳性NSCLC患者PD-L1表达特点及其与EGFR-TKIs治疗疗效关系的真实世界研究

Background and objective Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is the first choice for first-line treatment of advanced patients with EGFR positive non-small cell lung cancer (NSCLC). For advanced NSCLC patients with negative drive gene and positive programmed cell...

Descripción completa

Detalles Bibliográficos
Autores principales: CHEN, Ran, GAO, Xiang, XU, Fudong, ZHANG, Shucai, MA, Li, HU, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial board of Chinese Journal of Lung Cancer 2023
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106801/
https://www.ncbi.nlm.nih.gov/pubmed/37035884
http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.09

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106801/
https://www.ncbi.nlm.nih.gov/pubmed/37035884
http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.09

Ejemplares similares